Author Interviews, Heart Disease, JAMA, Johns Hopkins, Pulmonary Disease / 07.05.2019
COPD: Aclidinium Bromide (Tudorza Pressair) Has Favorable Safety Profile in Patients with CVD
MedicalResearch.com Interview with:
Robert A. Wise, M.D.
Professor of Medicine
Pulmonary and Critical Care
Johns Hopkins University School of Medicine
Baltimore, MD
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There has been a lingering controversy about the safety of long-acting anti-muscarinic agents (LAMA) as maintenance treatment for COPD in patients who have increased cardiovascular risk. This study enrolled participants with COPD who also had increased cardiovascular risk or known cardiovascular disease. Participants were randomly treated with either aclidinium bromide (Tudorza Pressair) or placebo.
Over 3 years of follow up there was no increased risk of adverse cardiovascular events. Moreover, the medication had a significant benefit in terms of reducing exacerbations and COPD hospitalizations. (more…)